Jefferies sees Arbutus (NASDAQ:ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK (GSK)/CureVac (CVAC) for H5N1 avian flu. The investment firm noted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback